Innovent Biologics Statistics
Total Valuation
Innovent Biologics has a market cap or net worth of HKD 68.02 billion. The enterprise value is 62.35 billion.
Market Cap | 68.02B |
Enterprise Value | 62.35B |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
Earnings Date | Nov 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Innovent Biologics has 1.63 billion shares outstanding. The number of shares has increased by 5.12% in one year.
Shares Outstanding | 1.63B |
Shares Change (YoY) | +5.12% |
Shares Change (QoQ) | +2.45% |
Owned by Insiders (%) | 7.04% |
Owned by Institutions (%) | 46.47% |
Float | 1.41B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 8.35 |
PB Ratio | 5.07 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -45.28 |
EV / Sales | 7.78 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.68, with a Debt / Equity ratio of 26.95.
Current Ratio | 2.68 |
Quick Ratio | 2.42 |
Debt / Equity | 26.95 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -18.36 |
Financial Efficiency
Return on equity (ROE) is -11.04% and return on invested capital (ROIC) is -6.61%.
Return on Equity (ROE) | -11.04% |
Return on Assets (ROA) | -5.19% |
Return on Capital (ROIC) | -6.61% |
Revenue Per Employee | 1.52M |
Profits Per Employee | -261,608 |
Employee Count | 4,872 |
Asset Turnover | 0.39 |
Inventory Turnover | 2.13 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.17% in the last 52 weeks. The beta is 0.12, so Innovent Biologics's price volatility has been lower than the market average.
Beta (5Y) | 0.12 |
52-Week Price Change | +24.17% |
50-Day Moving Average | 40.50 |
200-Day Moving Average | 39.21 |
Relative Strength Index (RSI) | 57.32 |
Average Volume (20 Days) | 5,459,133 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innovent Biologics had revenue of HKD 8.01 billion and -1.38 billion in losses. Loss per share was -0.86.
Revenue | 8.01B |
Gross Profit | 5.73B |
Operating Income | -1.70B |
Pretax Income | -1.38B |
Net Income | -1.38B |
EBITDA | -1.44B |
EBIT | -1.70B |
Loss Per Share | -0.86 |
Balance Sheet
The company has 9.27 billion in cash and 3.60 billion in debt, giving a net cash position of 5.67 billion or 3.48 per share.
Cash & Cash Equivalents | 9.27B |
Total Debt | 3.60B |
Net Cash | 5.67B |
Net Cash Per Share | 3.48 |
Equity (Book Value) | 13.35B |
Book Value Per Share | 8.23 |
Working Capital | 7.44B |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 71.58%, with operating and profit margins of -21.27% and -17.18%.
Gross Margin | 71.58% |
Operating Margin | -21.27% |
Pretax Margin | -17.18% |
Profit Margin | -17.18% |
EBITDA Margin | -18.03% |
EBIT Margin | -21.27% |
FCF Margin | n/a |
Dividends & Yields
Innovent Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.12% |
Shareholder Yield | -5.12% |
Earnings Yield | -2.06% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |